|
FDA Extends PDUFA Date for Biogen’s MS Treatment BG-12 to Late March
The FDA has extended the PDUFA date for Biogen Idec’s multiple sclerosis (MS) treatment BG-12 by three months to March 28, 2013.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives